Seven Bridges Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Seven Bridges Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,455	Closed	-$547K	–	76
2017 Q4	$547K	Hold	1,455	–	–	0.44%	62
2017 Q3	$651K	Buy	1,455 +205	+16%	+$97.5K	0.55%	56
2017 Q2	$614K	Buy	1,250 +151	+14%	+$66.1K	0.55%	53
2017 Q1	$426K	Buy	1,099 +219	+25%	+$81.2K	0.41%	71
2016 Q4	$323K	Sell	880 -45	-5%	-$17.1K	0.33%	79
2016 Q3	$372K	Sell	925 -339	-27%	-$136K	0.33%	77
2016 Q2	$441K	Sell	1,264 -561	-31%	-$216K	0.38%	70
2016 Q1	$658K	Buy	1,825 +400	+28%	+$165K	0.52%	59
2015 Q4	$774K	Buy	+1,425	New	+$772K	0.78%	40

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Seven Bridges Advisors's REGN Position: Q1 2018 in Review

Seven Bridges Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 1,455 shares — an estimated $547K sold.

Seven Bridges Advisors first reported a position in REGN in Q4 2015 and held it in 9 quarters. The position peaked at $774K in Q4 2015. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Seven Bridges Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Seven Bridges Advisors sold 1,455 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $547K.
Seven Bridges Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Seven Bridges Advisors's Regeneron Pharmaceuticals position peaked at $774K in Q4 2015.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Seven Bridges Advisors's 13F filing for Q1 2018, filed 9 May 2018.